Andreas Johansson – the new CTO
Andreas Johansson will take over as CTO on January 13, 2020, taking the place of Anders Sjögren who held this position since spring 2017. Anders remains in Lumito's organisation as a senior adviser and will continue to contribute to the company's development.
- I look forward to starting as Lumito’s CTO. This is an innovative, high-potential company, whose product can deliver enormous value to the market. I will work with continued technological development, with particular focus on the mix of software and hardware. Given my solid experience in systems design and product development, I believe I can be a valuable contributor in the intense phase in which Lumito is currently immersed", says Andreas Johansson
- We are delighted that Andreas is joining us and that Lumito will be benefiting from his solid software development experience, which he gained with product development companies. His skills are an excellent fit with our continued development strategy, especially now that Anders Sjögren is transitioning to an advisory role for the company", says Stefan Nilsson, CEO.
- It is with pleasure that I welcome Andreas to Lumito as my replacement to continue the work with full force. The company is in a very expansionary and intense phase, and Andreas will be better suited to oversee development in preparation for the upcoming product launch. Lumito's technology and products are coming onto the market with perfect timing; 2020 will be a very exciting year for us. Andrea's vast experience in software development is strategically important, as the analysis of human tissue will be an increasingly relevant part of Lumito's offering. The company's unique and patented technology for generating images of tissue samples provides completely new opportunities for diagnosis using image analysis and artificial intelligence.", Anders Sjögren concludes.
For more information, please contact:
Stefan Nilsson, CEO of Lumito AB (publ) Telephone: +46 767 78 59 05
Andreas Johansson, CTO of Lumito AB (publ) Email: email@example.com
Lumito in brief
Lumito is specialized in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents. Lumito’s share Lumito and warrant Lumito TO2 are traded at the NGM Nordic MTF marketplace.